GET DAILY SIGNALSRadiopharm Theranostics (RADX) Stock Slides -32% in Past Month on Dilution Pressures
Key Takeaways
- Radiopharm Theranostics (RADX) shares fell roughly 32% over the past 30 days, declining from about $1.12 to near $0.76 per American Depositary Share (ADS).
- The drop extends a broader downtrend: the stock is down roughly 67% over the last three months and approximately 82% year to date.
- A July 2026 capital raise—including a U.S. registered direct offering, warrants, and an Australian placement—sharply expanded the share count and remains the dominant overhang.
- Fiscal 2026 results showed a widening net loss and shrinking cash reserves, with management flagging a material going-concern uncertainty.
- Positive pipeline updates, including FDA clearance for a single Phase III trial of lead diagnostic RAD101, have not offset the selling pressure.
- For additional detail on this ticker, review RADX Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see AI-driven trading tools across a wide range of tickers.
Radiopharm Theranostics (RADX) Company Background and Sector Focus
Radiopharm Theranostics Limited is an Australian clinical-stage biopharmaceutical company focused on radiopharmaceutical products for diagnostic and therapeutic applications in precision oncology. It trades on the Australian Securities Exchange as RAD and on Nasdaq through American Depositary Shares as RADX, where each ADS equals 300 ordinary shares.
The pipeline covers peptide-, fatty acid-, and antibody-based platforms linked to radioisotopes, targeting markers including HER2, PD-L1, B7-H3, and KLK3. Key assets include diagnostic agents RAD101 and RAD301 plus therapeutic candidates such as RAD202, RAD204, RV01, and RAD402. A joint venture, Radiopharm Ventures LLC, with the University of Texas MD Anderson Cancer Center supports a broader radiotherapeutics platform. As a pre-revenue developer, the company draws attention mainly for clinical milestones, regulatory steps, and funding capacity.
RADX Stock Performance: Recent 30-Day Move Compared With the Quarter
Over the last 30 days, RADX declined about 32%, moving from a closing price near $1.12 on October 14 to around $0.76 per ADS. The decline was steady, with the shares posting successive lower lows and sitting near the bottom of the 52-week range.
The three-month view shows a sharper fall. Roughly three months earlier the ADS traded around $2.29; by mid-November it had reached about $0.76, a drop of roughly 67%. The shares remain more than 90% below the 52-week high of $16.25, pointing to an extended repricing rather than an isolated event.
Factors Behind the 30-Day Decline in RADX
The main pressure stems from ongoing dilution and balance-sheet issues. In July 2026 the company closed a US$4.1 million registered direct offering of 1,281,646 ADSs at $3.16 each, plus warrants at $3.79, along with an Australian placement and share purchase plan. Because each ADS represents 300 ordinary shares, the deal added roughly 384 million new ordinary shares, significantly widening the equity base.
Investor caution grew after fiscal 2026 results for the year ended June 30, 2026. Contract revenue fell 23.8% to $2.77 million while the loss attributable to owners widened 50.3% to $55.15 million. Cash reserves fell to $4.14 million from $29.12 million, and management noted that audited accounts would likely include a material going-concern uncertainty. Early November director share sales added to the cautious mood.
These factors outweighed positive clinical updates. At a Deutsche Bank investor conference in mid-November, management highlighted encouraging early data, including FDA agreement to move RAD101 into a single Phase III trial and a 50% response rate for RAD204 at dose level three. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Drivers of the Three-Month Performance Trend
The quarterly decline reflects a wider story of aggressive fundraising against a limited cash runway. The July financing, approved by shareholders in September, brought warrants and options that created a clear dilution overhang, sustaining downward pressure even as pipeline progress continued.
Declining cash and the flagged going-concern uncertainty have kept attention on financing risk rather than clinical catalysts. Although the lead diagnostic program has advanced and early therapeutic data shows activity, the market has focused more on capital position and the expanded share count than on near-term scientific milestones.
Key Areas to Monitor for RADX Going Forward
Looking ahead, attention will likely center first on financing and liquidity—whether the company raises more capital, completes partnerships or licensing deals for its diagnostic assets, or issues additional securities. The going-concern flag makes cash management a key variable.
Clinically, catalysts include further progress on the single Phase III trial for RAD101, additional dose-escalation data for RAD202 and RAD204, and any partnering news for the imaging programs. Management has flagged 2027 as a year with multiple potential milestones, such as dose-escalation updates and a possible shift to Phase II dosing. Regulatory outcomes, trial enrollment, and sentiment toward small-cap radiopharmaceutical developers will also influence direction. These are factual considerations, not investment recommendations.
Exploring AI-Driven Trading Approaches
I often review Tickeron’s AI Trading Bots when looking at volatile names like RADX to see how automated strategies are performing across different timeframes and risk levels. The platform highlights top-performing bots that users can compare for short-term momentum or longer positioning ideas, giving an extra data-driven angle on market activity without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Momentum Indicator for RADX turns negative, indicating new downward trend
RADX saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator turned negative. In 42 of the 46 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RADX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RADX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RADX's RSI Oscillator exited the oversold zone, 6 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for RADX just turned positive on October 13, 2026. Looking at past instances where RADX's MACD turned positive, the stock continued to rise in 12 of 16 cases over the following month. The odds of a continued upward trend are 75%.
Following a +10.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where RADX advanced for three days, in 63 of 79 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.263) is normal, around the industry mean (3.498). P/E Ratio (-0.051) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. RADX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RADX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement